Artificial intelligence (AI) is increasingly integrated into oncology for improving early detection and disease management. A new machine learning model developed at the University of Sharjah accurately predicts early pancreatic cancer and forecasts patient prognosis. Adaptive Biotechnologies has partnered with Roche's Flatiron Health to embed its ClonoSeq minimal residual disease (MRD) assay into electronic medical records, enhancing workflow efficiency in community cancer centers across the US. These AI-driven tools promise to facilitate personalized oncology care and expand accessibility.